First oncolytic virus approved for melanoma immunotherapy

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Oncoimmunology

• Publication date

  2016-01-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/2162402X.2015.1115641PMID 26942095PMCID PMC4760283
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Trial Watch—Oncolytic viruses and cancer therapy

  2016cited by this paper
• Oncolytic viruses: a new class of immunotherapy drugs

  2015cited by this paper
• Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.

  2015cited by this paper
• Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

  2015influential reference
• Oncolytic Virus Immunotherapy for Melanoma

  2015cited by this paper
• Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma

  2015cited by this paper
• Oncolytic viruses get a boost with first FDA-approval recommendation

  2015cited by this paper
• Type I interferons in anticancer immunity

  2015cited by this paper
• Essential versus accessory aspects of cell death: recommendations of the NCCD 2015

  2014cited by this paper
• Classification of current anticancer immunotherapies

  2014cited by this paper
• Consensus guidelines for the detection of immunogenic cell death

  2014cited by this paper
• Trial watch

  2014cited by this paper
• Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death

  2014cited by this paper
• Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization

  2014cited by this paper
• Two is better than one

  2014cited by this paper
• Engineering HSV-1 vectors for gene therapy.

  2014influential reference
• Healing after death: antitumor immunity induced by oncolytic adenoviral therapy

  2014cited by this paper
• Trial Watch: Radioimmunotherapy for oncological indications

  2014cited by this paper
• Trial Watch:

  2014cited by this paper
• Trial Watch

  2014cited by this paper
• Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.

  2013cited by this paper
• Antitumor immune responses mediated by dendritic cells

  2013cited by this paper
• Immunogenic cell death in cancer therapy.

  2013cited by this paper
• Rewiring cancer cell death to enhance oncolytic viro-immunotherapy

  2013cited by this paper
• Cancer immunotherapy turns viral

  2013cited by this paper
• ONCOLYTIC VIROTHERAPY

  2012cited by this paper
• Clinical development of oncolytic viruses in China.

  2012cited by this paper
• Trial Watch: Monoclonal antibodies in cancer therapy

  2012cited by this paper
• Trial Watch

  2012cited by this paper
• Antiviral Drugs for Viruses Other Than Human Immunodeficiency Virus

  2011cited by this paper
• OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma.

  2010cited by this paper
• Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma

  2010cited by this paper
• Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.

  2009cited by this paper
• Oncolytic virotherapy.

  2008cited by this paper
• Antiviral prodrugs – the development of successful prodrug strategies for antiviral chemotherapy

  2006cited by this paper
• A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor

  2006cited by this paper
• ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

  2003influential reference
• The herpes simplex virus US11 protein effectively compensates for the gamma1(34.5) gene if present before activation of protein kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic translation initiation factor 2.

  1998cited by this paper
• The Second-Site Mutation in the Herpes Simplex Virus Recombinants Lacking the γ134.5 Genes Precludes Shutoff of Protein Synthesis by Blocking the Phosphorylation of eIF-2α

  1998cited by this paper
• The Herpes Simplex Virus US11 Protein Effectively Compensates for the γ134.5 Gene if Present before Activation of Protein Kinase R by Precluding Its Phosphorylation and That of the α Subunit of Eukaryotic Translation Initiation Factor 2

  1998cited by this paper

• Oncolytic Viruses in Cancer Immunotherapy: From Molecular Engineering to Clinical Translation

  2026cites this paper
• Dual role of rVSV vectors in prophylactic and therapeutic innovation: a comprehensive bibliometric and clinical trial perspective.

  2026cites this paper
• Replication-competent adenoviral platform for in situ production of immunotherapeutic RNA aptamers targeting 4-1BB

  2026cites this paper
• Oncolytic viruses: advanced strategies in cancer therapy

  2026cites this paper
• Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery

  2026cites this paper
• Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors

  2026cites this paper
• Viral vector research in human gene therapy: basic principles, alternative evaluation models, and clinical applications.

  2026cites this paper
• Oncolytic Virus Therapy in a New Era of Immunotherapy, Enhanced by Combination with Existing Anticancer Therapies: Turn up the Heat!

  2025cites this paper
• Glutathione-responsive self-assembling peptide coated Salmonella for antitumor therapy.

  2025cites this paper
• Clinical Approaches for the Management of Skin Cancer: A Review of Current Progress in Diagnosis, Treatment, and Prognosis for Patients with Melanoma

  2025cites this paper
• Immune Modulation and Immunotherapy in Solid Tumors: Mechanisms of Resistance and Potential Therapeutic Strategies

  2025cites this paper
• Oncolytic virotherapy: molecular mechanisms, delivery strategies, and translational insights.

  2025cites this paper
• Human Melanoma Skin Cancer Models: A Step Towards Drug Testing & Target Therapy

  2025cites this paper
• Harnessing live vectors for cancer vaccines: Advancing therapeutic immunotherapy

  2025cites this paper
• Investigating the potential of oncolytic viruses in the treatment of melanoma: where do we go from here?

  2025cites this paper
• Oncolytic Virus Therapies in Malignant Gliomas: Advances and Clinical Trials

  2025influential citation
• Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression

  2025cites this paper
• Advances in Oncolytic Viral Therapy in Melanoma: A Comprehensive Review

  2025cites this paper
• Oncolytic Vaccinia Virus Armed with GM-CSF and IL-7 Enhances Antitumor Immunity in Pancreatic Cancer

  2025cites this paper
• Unlocking the potential: advancements and applications of gene therapy in severe disorders

  2025cites this paper
• Oncolytic Virus as a New Treatment Technology in Cancer

  2025influential citation
• A comprehensive review redefining viruses as therapeutic agents in cancer treatment

  2025cites this paper
• Improving CD3 bispecific antibody therapy in solid tumors using combination strategies

  2025cites this paper
• Precision oncolytic viral therapy in colorectal cancer: Genetic targeting and immune modulation for personalized treatment (Review)

  2025cites this paper
• Local M1 Macrophage Reprogramming with Gluconic Acid-Coated Selenium Nanoparticles

  2025cites this paper
• Epigenetic modulation by oncolytic viruses: Implications for cancer therapeutic efficacy.

  2025cites this paper
• Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landscape of Immunotherapy

  2025cites this paper
• Unmasking the potential: mechanisms of neuroinflammatory modulation by oncolytic viruses in glioblastoma

  2025cites this paper
• Oncolytic virotherapy and tumor microenvironment modulation

  2025cites this paper
• Comparative real-world outcomes of stage III melanoma patients treated with talimogene laherparepvec or interleukin 2

  2025cites this paper
• Tumor neoantigens as key drivers of significant anti - tumor immunity in triple - negative breast cancer mouse models

  2025cites this paper
• Intratumoral immunotherapy prior to cancer surgery, a promising therapeutic approach

  2025cites this paper
• Gene editing in cancer therapy: overcoming drug resistance and enhancing precision medicine

  2025cites this paper
• Targeting Microbe-Mediated Macrophage Education: A Novel Paradigm in Cancer Immunotherapy

  2025cites this paper
• Turning tumor microenvironmental foes to friends: A new opportunity for thyroid cancer therapy and redifferentiation.

  2025cites this paper
• Lipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy

  2025cites this paper
• Constructing the cure: engineering the next wave of antibody and cellular immune therapies

  2025cites this paper
• Bridging the gap for diverse applications of parasites as advanced cancer therapeutics: current progress and future directions

  2025cites this paper
• The evolving landscape of oncolytic virus immunotherapy: combinatorial strategies and novel engineering approaches

  2025cites this paper
• Caprine herpes virus-1 reduces cell viability and enhances chemosensitivity in breast cancer cells

  2025cites this paper
• CCL19-armed recombinant influenza virus inhibited colorectal cancer growth by remodeling tumor microenvironment

  2025cites this paper
• Harnessing immunotherapy: cancer vaccines as novel therapeutic strategies for brain tumor

  2025cites this paper
• Oncolytic Virotherapy in Colorectal Cancer: Mechanistic Insights, Enhancer Strategies, and Translational Combinations

  2025cites this paper
• Latest insights into oncolytic viro-immunotherapy with vesicular stomatitis virus.

  2025cites this paper
• Engineering the tumor microenvironment: oncolytic NDV to facilitate CAR-T cell therapy

  2025cites this paper
• A New Era in Oncology: Clinical Insights Into the Application of Oncolytic Viruses

  2025cites this paper
• Immune Checkpoint Inhibitors Combined with Oncolytic Virotherapy: Synergy, Heterogeneity, and Safety in Cancer Treatment

  2025cites this paper
• Dynamic Evolution of the Tumor Immune Microenvironment in Malignant Tumors and Emerging Therapeutic Paradigms

  2025cites this paper
• Overcoming IGF1R-Mediated Resistance to Oncolytic HSV1 and Radiotherapy via Triple Combination Therapy

  2025cites this paper
• Solid tumor rejection using personalized incompatible human leukocyte antigen (HLA) and blood group ABH antigens

  2025cites this paper
• Transferrin-binding domain inserted-adenovirus hexon engineering enables systemic immune evasion and intratumoral T-cell activation

  2025cites this paper
• Delivering living medicines with biomaterials

  2025cites this paper
• Oncolytic Viruses and Immunotherapy for the Treatment of Uveal Melanoma and Retinoblastoma: The Current Landscape and Novel Advances

  2025cites this paper
• Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology

  2025cites this paper
• Therapeutic Colorectal Cancer Vaccines: Emerging Modalities and Translational Opportunities

  2025cites this paper
• The multilayered control of acetylation during adenovirus-based immunotherapy of cancer

  2025cites this paper
• The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner

  2024cites this paper
• Nanoparticle-mediated active and passive drug targeting in oral squamous cell carcinoma: current trends and advances.

  2024cites this paper
• Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice

  2024cites this paper
• Cancer vaccines: Target antigens, vaccine platforms and preclinical models.

  2024cites this paper
• Oncolytic herpes simplex viruses designed for targeted treatment of EGFR-bearing tumors

  2024cites this paper
• Cancer vaccines: an update on recent achievements and prospects for cancer therapy

  2024cites this paper
• Disentangling Anti‐Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab

  2024cites this paper
• A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first‐line treatment for patients with melanoma in‐transit metastases

  2024cites this paper
• Molecular and modular intricacies of precision oncology

  2024cites this paper
• Advances in the therapeutic study of oncolytic virus in colorectal cancer

  2024cites this paper
• Advances in the management of regionally metastatic melanoma.

  2024cites this paper
• Unlocking potential: Herpes Simplex Virus Type 1-based gene therapy in functional urology

  2024cites this paper
• Oncolytic Virotherapies and Adjuvant Gut Microbiome Therapeutics to Enhance Efficacy Against Malignant Gliomas

  2024influential citation
• The use of viruses in anti-cancer therapies – new achievements and challenges

  2024cites this paper
• Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy

  2024cites this paper
• Specific Cell Targeting by Toxoplasma gondii Displaying Functional Single-Chain Variable Fragment as a Novel Strategy; A Proof of Principle

  2024cites this paper
• Enhanced IL-12 transgene expression improves oncolytic viroimmunotherapy

  2024cites this paper
• Stabilization of an infectious enveloped virus by spray-drying and lyophilization.

  2024cites this paper
• Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance

  2024cites this paper
• Recent advancements in the diagnosis and treatment of acral melanoma

  2024cites this paper
• Pharmacokinetic enhancement of oncolytic virus M1 by inhibiting JAK‒STAT pathway

  2024cites this paper
• The Potential of Oncolytic Virotherapy in the Treatment of Head and Neck Cancer: A Comprehensive Review

  2024cites this paper
• Lung cancer vaccination from concept to reality: A critical review of clinical trials and latest advances.

  2024cites this paper
• Integrating system biology and intratumor gene therapy by trans-complementing the appropriate co-stimulatory molecule as payload in oncolytic herpes virus

  2024cites this paper
• Recent advancements in targeted protein knockdown technologies—emerging paradigms for targeted therapy

  2023cites this paper
• Personalizing Oncolytic Immunovirotherapy Approaches

  2023cites this paper
• Overview of current melanoma therapies

  2023cites this paper
• [Oncolytic viruses: Actors and deliverers of therapeutic proteins against tumors].

  2023cites this paper
• NK cells propagate T cell immunity following in situ tumor vaccination.

  2023cites this paper
• Dual peptides-modified cationic liposomes for enhanced Lung cancer gene therapy by a gap junction regulating strategy

  2023cites this paper
• Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer

  2023cites this paper
• Optimal delivery of RNA interference by viral vectors for cancer therapy.

  2023cites this paper
• Engineering approaches for innate immune-mediated tumor microenvironment remodeling

  2023cites this paper
• Rational selection of an ideal oncolytic virus to address current limitations in clinical translation.

  2023cites this paper
• Oclacitinib and Myxoma Virus Therapy in Dogs with High-Grade Soft Tissue Sarcoma

  2023cites this paper
• Advancements and challenges in oncolytic virus therapy for gastrointestinal tumors.

  2023cites this paper
• Current and preclinical treatment options for Merkel cell carcinoma

  2023cites this paper
• Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy

  2023cites this paper
• Oncolytic Virotherapy.

  2023cites this paper
• Urchin-like ceria nanoparticles for enhanced gene therapy of osteoarthritis

  2023cites this paper
• Nasal administration of recombinant Neospora caninum secreting IL-15/IL-15Rα inhibits metastatic melanoma development in lung

  2023cites this paper
• Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1

  2023cites this paper
• Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response

  2023cites this paper
• Triple-Negative Breast Cancer: Basic Biology and Immuno-Oncolytic Viruses

  2023cites this paper